GI Surgery – Liver
Fluorescence-guided surgery: comprehensive review
18 May, 2023 | 13:34h | UTCFluorescence-guided surgery: comprehensive review – BJS Open
Commentary on Twitter
Find all you ever wanted to know about the current state of fluorescence-guided surgery 🟢🔬🔪in our latest comprehensive review by @BJSurgery editor @paulo_sutt et al. Absolutely worth reading!https://t.co/Tgrj4UvOzV@BJSAcademy @juliomayol @young_bjs #SoMe4Surgery #MedTwitter pic.twitter.com/ReArdO1LOs
— BJS Open (@BjsOpen) May 17, 2023
EASL-ILCA Clinical practice guidelines on the management of intrahepatic cholangiocarcinoma
9 May, 2023 | 14:47h | UTC
Commentary on Twitter
🆕#CPG in press❕
EASL-ILCA Clinical Practice Guidelines on the management of #IntrahepaticCholangiocarcinoma
🆓Find it here👉https://t.co/buM8rgBU1F@EASLedu@EASLnews#iCCA#LiverTwitter pic.twitter.com/raR983x0qk
— Journal of Hepatology (@JHepatology) April 20, 2023
Review | Multidisciplinary management in the treatment of intrahepatic cholangiocarcinoma
28 Apr, 2023 | 13:03h | UTC
Perspective | Liver transplantation for patients with severe acute on chronic liver failure: it is time to change paradigms
25 Apr, 2023 | 14:37h | UTC
Commentary on Twitter
Liver #Tx in severe acute on chronic failure
➡️ #ICU care crucial in ACLF-3
➡️ improve referrals to LT centers & pre-LT workup
➡️ to decide to put pt on waitlist consider donor shortage/collective utility of LT
➡️ identifying transplantability window
🖇️ https://t.co/VZxDyZ1k74 pic.twitter.com/6YOcd5rzMu— Intensive Care Medicine (@yourICM) April 19, 2023
Overcoming size disparity in liver transplant access: prioritizing smaller donors for smaller candidates
3 Apr, 2023 | 13:41h | UTCAssociation of Body Surface Area With Access to Deceased Donor Liver Transplant and Novel Allocation Policies – JAMA Surgery (free for a limited period)
Invited Commentary: Addressing Size-Based Disparities in Liver Transplant – JAMA Surgery (free for a limited period)
Commentary on Twitter
In this study, liver waitlist candidates with the smallest body surface areas had a disadvantage due to size. Prioritizing allocation of smaller liver donors to smaller candidates may help overcome this disparity. https://t.co/p5F76Hgzm0
— JAMA Surgery (@JAMASurgery) March 30, 2023
Review | Platelet aggregation inhibitors and anticoagulants in gastroenterological and visceral surgical procedures
1 Mar, 2023 | 14:03h | UTC
Post-transplant biliary complications: advances in pathophysiology, diagnosis, and treatment
3 Feb, 2023 | 14:01h | UTC
M-A | Major complications and mortality after resection of intrahepatic cholangiocarcinoma
3 Feb, 2023 | 13:43h | UTC
M-A | Impact of perioperative steroid administration in patients undergoing elective liver resection
19 Jan, 2023 | 14:00h | UTC
ERAS Guidelines for perioperative care for liver surgery.
1 Nov, 2022 | 12:16h | UTCRelated:
Complete List of Enhanced Recovery After Surgery (ERAS) Society Guidelines
Systematic Review | Contrast‐enhanced ultrasound for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease.
5 Sep, 2022 | 14:13h | UTC
Meta-analysis of observational studies | In patients with hepatocellular carcinoma, intraoperative blood salvage during liver transplantation appears safe.
30 Aug, 2022 | 12:03h | UTC
Review | New concepts in the treatment of hepatocellular carcinoma.
24 Aug, 2022 | 13:56h | UTCNew concepts in the treatment of hepatocellular carcinoma – UEG Journal
Review | Acute liver failure management and liver transplantation.
15 Aug, 2022 | 11:41h | UTCCAQ Corner: Acute liver failure management and liver transplantation – Liver Transplantation
RCT | Lenvatinib combined with transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma.
5 Aug, 2022 | 13:50h | UTCLenvatinib Combined With Transarterial Chemoembolization as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Phase III, Randomized Clinical Trial (LAUNCH) – Journal of Clinical Oncology (link to abstract – $ for full-text)
Commentary: Adding TACE to Lenvatinib Boosts Survival in Advanced Liver Cancer — In China-based trial, overall survival in first-line improved by 6 months versus lenvatinib alone – MedPage Today (free registration required)
Case-Control Study | Survival benefit of living-donor liver transplant.
4 Aug, 2022 | 13:59h | UTCSurvival Benefit of Living-Donor Liver Transplant – JAMA Surgery
Commentaries:
Just How Low a Model for End-stage Liver Disease Score Benefits From Living-Donor Liver Transplant? – JAMA Surgery (free for a limited period)
Low MELD Score No Barrier to Long Survival After Living-Donor Transplant — End-stage liver disease patients with scores as low as 11 achieved survival of 13 years or beyond – MedPage Today (free registration required)
M-A | Repeat hepatic resection vs. percutaneous ablation for the treatment of recurrent hepatocellular carcinoma.
4 Aug, 2022 | 13:27h | UTC
Commentary on Twitter
Recurrent #HCC after resection: re-resect or ablate?
📰#systematicreviewRedo-Resection has:
– ⏫Morbidity 17% vs 3%
– ⏫ recurrence free survival (HR 0.79)
– ⚖️ overall survival (HR 0.93 (0.83-1.04))https://t.co/WWwsHNkNQ9#SoMe4Surgery #some4hpb@SEIQuirurgica @asgbi pic.twitter.com/h4apdpY7eh— BJS Open (@BjsOpen) May 6, 2022
M-A | Evidence on indications and techniques to increase the future liver remnant in children undergoing extended hepatectomy.
22 Jul, 2022 | 11:33h | UTC
Review | Liver biopsy in patients with alcohol-associated liver disease with acute-on-chronic liver failure.
22 Jul, 2022 | 11:28h | UTC
Cystic liver lesions: a pictorial review.
18 Jul, 2022 | 10:48h | UTCCystic liver lesions: a pictorial review – Insights into Imaging
Hypertensive disorders in pregnancy complicated by liver rupture or hematoma: a systematic review of 391 reported cases.
12 Jul, 2022 | 11:48h | UTC
Review: Portal vein thrombosis in cirrhosis.
15 Jun, 2022 | 10:38h | UTCPortal Vein Thrombosis in Cirrhosis – Journal of Clinical and Experimental Hepatology
Causes of liver cancer are changing around the world: some up, some down.
13 Jun, 2022 | 07:54h | UTCNews Release: Causes of Liver Cancer are Changing Around the World: Some Up, Some Down – UC San Diego Health
Original Study: Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer – Cell Metabolism (link to abstract – $ for full-text)
ERAS Guidelines for perioperative care in elective abdominal and pelvic surgery at primary and secondary hospitals in low–middle-income countries.
1 Jun, 2022 | 12:08h | UTCRelated:
Complete List of Enhanced Recovery After Surgery (ERAS) Society Guidelines
Update on perioperative management of patients undergoing surgery for liver cancer.
1 Jun, 2022 | 11:11h | UTC